Logo

Taiho’s Lonsurf (trifluridine/tipiracil) + Bevacizumab Receives EC’s Approval as 3L Treatment of Refractory Metastatic Colorectal Cancer

Share this

Taiho’s Lonsurf (trifluridine/tipiracil) + Bevacizumab Receives EC’s Approval as 3L Treatment of Refractory Metastatic Colorectal Cancer

Shots:

  • The EC has approved Lonsurf + bevacizumab for adult patients with mCRC who received 2 prior anti-cancer treatments incl. fluoropyrimidine-, oxaliplatin & irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. The trial was conducted by Servier & Taiho Oncology
  • The approval was based on the P-III trial (SUNLIGHT) evaluating trifluridine/tipiracil + bevacizumab vs trifluridine/tipiracil alone in a ratio (1:1) in 492 patients. The primary objective was to evaluate trifluridine/tipiracil + bevacizumab in terms of OS & 2EPs were PFS, ORR, DCR & QoL, safety & tolerability
  • The marketing authorization is valid in 27 EU countries, Iceland, Northern Ireland, Liechtenstein & Norway. Lonsurf, an oral nucleoside antitumor agent discovered & developed by Taiho Pharmaceutical

Ref: Taiho | Image: Taiho

Related News:- Taiho Oncology Reports the US FDA Acceptance of sNDA for Priority Review of Lonsurf (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions